Pharma BD Deal Intelligence

Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA

2013 · Acquisition/Merger · $305M · Complete

Announcement Sentiment

Strongly positive

Watson acquired Belgium-based Uteron Pharma for $150M cash upfront + up to $155M milestones; expanded Global Brands women's health pipeline (contraception, infertility, IUDs).

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jan 23, 2013
Closed Jan 23, 2013
Deal value $305M
Deal type Acquisition/Merger
Therapeutic area Contraception, infertility / women's health
Indications Contraception, infertility / women's health
Key assets Levosert IUD (levonorgestrel); Diafert (oocyte quality immunoassay); novel oral contraceptive
Mechanism Levonorgestrel IUD; G-CSF immunoassay for IVF egg quality

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals